Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration

Uri Soiberman*, Anat Loewenstein

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Age-related macular degeneration (AMD) is a leading cause of severe visual loss in the elderly. A long path of clinical trials with various treatment modalities has led to novel contemporary treatments, including bevacizumab (Avastin®; Genentech, CA, USA) and ranibizumab (Lucentis ®; Genentech). These drugs have revolutionized the approach to neovascular AMD, and today they are one of the major treatments for the disease. While both these drugs are reported to be effective, with somewhat stronger clinical evidence for ranibizumab, debate continues as to which is most effective in the treatment of AMD. Large-scale studies currently underway are expected to shed light on the subject. Based on the evolving data, as well as on our clinical experience, we believe that the two drugs, while harboring different biological characteristics and potential clinical differences, still share many similar characteristics in their efficacy and safety. The similarities and differences in efficacy and safety will be demonstrated in prospective comparative trials currently taking place.

Original languageEnglish
Pages (from-to)603-615
Number of pages13
JournalExpert Review of Ophthalmology
Issue number5
StatePublished - Oct 2010


  • age-related macular degeneration
  • bevacizumab
  • neovascular maculopathy
  • ranibizumab
  • vascular endothelial growth factor


Dive into the research topics of 'Bevacizumab versus ranibizumab for the treatment of neovascular age-related macular degeneration'. Together they form a unique fingerprint.

Cite this